Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
/in Hypernephroma, International Publications /von 2007-10-01 / J. Immunother. 2007 Oct;30(7):749-61Dendritic cell immunotherapy for stage IV melanoma
/in International Publications, Malignant Melanoma /von 2007-10-01 / Melanoma Res. 2007 Oct;17(5):316-22Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses
/in International Publications, Micronutrients /von 2007-10-01 / Br. J. Nutr. 2007 Oct;98 Suppl 1:S29-35Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines
/in Colorectal Cancer, International Publications /von 2007-10-01 / Cancer 2007 Oct;110(7):1469-77Apoptic renal carcinoma cells are better inducers of cross-presenting activity than their primary necrotic counterpart
/in Hypernephroma, International Publications /von 2007-10-01 / Int J Immunopathol Pharmacol 2007 Oct-Dec;20(4):707-17Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis
/in International Publications, Malignant Lymphoma /von 2007-09-25 / J Transl Med 2007 Sep;5:46Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc(Min/+) mice
/in Dendritic Cells, Hyperthermia, International Publications /von 2007-09-24 / Cancer Sci. 2007 Dec;98(12):1930-5Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial
/in Cervical Cancer, International Publications /von 2007-09-19 / Int. J. Radiat. Oncol. Biol. Phys. 2008 Mar;70(4):1176-82Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination
/in International Publications, Malignant Lymphoma /von 2007-09-15 / Cancer Res. 2007 Sep;67(18):8450-5IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de